PROBLEM TO BE SOLVED: To provide prophylactic or therapeutic means against atrophic type age-related macular degeneration for which there is no effective treatment.SOLUTION: According to the present invention, there is provided a prophylactic or therapeutic agent for atrophic type age-related macular degeneration, the agent comprising as an active ingredient Aflibercept, which is a recombinant fusion glycoprotein in which the parts of extracellular domains of human VEGF receptor 1 and receptor 2 are linked to the Fc domain of human IgG1. Aflibercept inhibits the activation of a VEGF signal by binding to VEGF-A, VEGF-B, and PlGF with high affinity. In other words, Aflibercept trapped not only PIG but also VEGF (that induces angiogenesis and exacerbates exudative age-related macular degeneration, while having a neuroprotective aspect), and exerts its effect thereon. Therefore, if Aflibercept is applied to atrophic type age-related macular degeneration, as a result of the inhibition of the action of VEGF, it is not possible to obtain the retinoprotective effect, such as one observed when the anti-PlGF antibody is applied.SELECTED DRAWING: None【課題】有効な治療法のない萎縮型加齢黄斑変性症に対する予防又は治療手段の提供。【解決手段】ヒトＶＥＧＦ受容体１と受容体２の細胞外ドメインの一部をヒトＩｇＧ１のＦｃドメインと結合させた遺伝子組換え融合糖タンパク質である、アフリベルセプトを有効成分とする、萎縮型加齢黄斑変性症の予防又は治療薬。アフリベルセプトはＶＥＧＦ－Ａ、ＶＥＧＦ－Ｂ及びＰｌＧＦと高親和性に結合することにより、ＶＥＧＦシグナルの活性化を阻害する。即ち、アフリベルセプトはＰｌＧＦのみならず、ＶＥＧＦ（滲出型加齢黄斑変性症においては血管新生を誘導し、増悪的に働くが、神経保護的な面も持ち合わせている）もトラップし、その作用効果を発揮する。従って、アフリベルセプトを萎縮型加齢黄斑変性症に対して適用すれば、ＶＥＧＦの作用が阻害される結果として、抗ＰｌＧＦ抗体を適用した場合に認められたような網膜保護効果が得られない。【選択図】なし
